Page last updated: 2024-09-03

24-hydroxycholesterol and Orphan Diseases

24-hydroxycholesterol has been researched along with Orphan Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Berry-Kravis, E; Bianconi, S; Brewer, CC; Davidson, CD; Farhat, NY; Jiang, X; Kao, M; Keener, LA; King, KA; Machielse, BN; McKew, JC; Ory, DS; Ottinger, EA; Pavan, WJ; Porter, FD; Rao, R; Sidhu, R; Silber, SA; Soldatos, A; Solomon, B; Thurm, A; Vite, CH; Walkley, SU; Walters, KA; Weissfeld, L; Xu, X1

Trials

1 trial(s) available for 24-hydroxycholesterol and Orphan Diseases

ArticleYear
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adolescent; Biomarkers; Calbindins; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Fatty Acid Binding Protein 3; Female; Hearing Loss, High-Frequency; Humans; Hydroxycholesterols; Injections, Spinal; Male; Niemann-Pick Disease, Type C; Rare Diseases; Young Adult

2017